Pharmatalkradio

In this podcast, hear a keynote session from the 2021 Chief Medical Officer Summit 360˚ with Dr Ron Cohen on his journey founding and building Acorda Therapeutics and leading the company as an MD CEO for 26 years. Dr Cohen also shares advice on how CMOs can best collaborate with their CEOs and add value to their companies. Learn more about the 10th annual Chief Medical Officer Summit taking place April 4-5, 2022 here.

Dr Viney joined the CMO Summit 360° in October 2021 to share her incredible journey in drug discovery and development, founding and leading Pandion Therapeutics and joining the advisory boards of multiple biotech companies.  Learn more about the 10th annual CMO Summit 360° taking place April 4-5, 2022 here.

Conference Producer, Andrew Goldstein, walks through what you can expect to learn and who you'll hear from at the upcoming Chief Medical Officer Summit 360º taking place April 4-5, 2022 in Boston, MA, including: Clinical development and operationsRelationships within the C-suite and team buildingThe role of the CMO in biotech financingExternal communicationsProfessional development For more information, click here.

About the Episode:  In this podcast, we discuss the topic of clinical sites shifting to using the own technologies in sponsored trials and how it can advance (and maintain the pace of) clinical research. Our guest, Bryan Spielman, Chief Growth Officer at Advarra lays out the current burden being faced by performing sponsor trials. Mr Spielman also talks about the work Advarra has led in bringing together sites, CROs and sponsors to brainstorm new solutions, and the path forward to encourage wider conversation, acceptance and adoption.   Key Takeaways: Identifying current burdens faced by sitesUnderstanding current attitudes towards site-owned technologySteps forward to benefit both sides of clinical research   About the Speaker:  Bryan Spielman, MBA, is Chief Growth Officer at Advarra and is responsible for driving Advarra’s corporate strategy, mergers and acquisitions, strategic partnerships, and corporate marketing. Spielman brings over 25 years of business development and corporate strategy experience

About the Episode:  Daniel Chen, MD, PhD, Immuno-Oncology 360º 2022 Strategic Advisor, Physician Scientist, Cancer Immunotherapy and Board of Directors, Society for Immunotherapy of Cancer (SITC) and co-author of the Cancer Immunity Cycle, discusses five talks he is excited for, and why, at the upcoming Immuno-Oncology360 conference. The 2022 summit will be held March 16th through the 18th, 2022 at the New York Marriott Brooklyn Bridge. For more information, and the full agenda, visit www.io360summit.com.    5 Top Topics To Watch from Dan Chen:  ctDNA Guiding Adjuvant ImmunotherapyClinical Data on PSMA BiTeNovel Approaches to Expand the Therapeutic Index of T cell EngagersSynthetic BiologyIO360° Debate: NK-Cars vs T cell- CARs

This 7 minute podcast summarizes what you can expect at the 8th annual Immuno-Oncology 360° conference. IO360˚convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers. Keynotes include: Dr Gregg Semenza, Johns Hopkins University School of MedicineDr Rachel Haurwitz, Caribou BiosciencesDr Christine Brown, City of HopeDr Suzanne Topalian, Johns Hopkins UniversityDr Andrew Baum, Citi Key topic areas include: Discovery/Preclinical ScienceCell & Gene TherapyTranslational ScienceBispecificsClinical DevelopmentsNeoadjuvant/Adjuvant DataEmerging BiomarkersCytokinesClinical OperationsIO CombinationsImaging AdvancementsBusiness Developments The conference takes place February 16-18, 2022 at the New York Marriott Brooklyn Bridge, New York City, NY. For more information please visit www.io360summit.com or contact us at service@tcfllc.org

Conference Producer, Mark Scherzer, talks through what to expect at the upcoming Patients as Partners EU virtual conference taking place 24-25 January 2022.  The 6th annual conference will bring together pharma, biotech, CROs and technologists to figure out how to advance patient involvement in medicines development. Experts from Novartis, Pfizer, Merck, EMD Serono, Janssen, Johnson & Johnson, GSK, Ipsen, UCB, Takeda, AbbVie, Noema Pharma, Gilead Sciences, and Pierre Fabre will gather with patient advocacy to address: Outcome measures that matter most to patients  Patient Experience Data for regulatory submissionsCompliance barriers to advance patient involvementIncreasing diversity in clinical researchPatient involvement in Turkey and Eastern EuropeImpacting clinical research through carer InputPatient involvement in the design and execution of platform trialsPatient access to research through digital innovation

About the Episode: How can artificial intelligence maintain the pace of clinical trials from the COVID-19 pandemic to bring therapeutics to patients faster? Suresh Katta, CEO and founder of Saama Technologies, sits down to discuss exactly how artificial intelligence can be utilized to design better trials from the start, reduce costs and benefit patients and pharma in the long run.    Key Takeaways: How to create broader adoption and change management of new technologiesCreating the best protocol design from the start, without pricey and time-consuming amendmentsHow AI can reduce costs, as well as timelines About the Speaker: Suresh Katta founded Saama Technologies in 1997, well before the collective global corporate conscience was aware of the extraordinary opportunities – and significant challenges – inherent in big data. He is a frequent contributor to industry publications and a featured speaker at industry conferences. He earned his M.S. in Computer Engineering at the University of Southwest Louisia

About the Episode: How can therapeutics like biologics and small molecule drugs evolve in their delivery? Finn Doyle, SVP and General Manager of ENHANZE® at Halozyme, sits down to discuss exactly how these innovative therapeutics can be delivered subcutaneously where they have previously only been administered via IV, the impacts of doing so, and the keys to successful drug delivery collaborations.  Key Takeaways:  How switching to a SC delivery model impacts patients, healthcare providers and drug development companies Keys to successful partnerships and collaborations How Halozyme's ENHANZE® technology enables the shift from IV to SC About the Speaker: Finn Doyle joined Halozyme in May of 2021 as the Senior Vice President and General Manager of ENHANZE®. She is responsible for overseeing Halozyme’s ENHANZE® drug delivery technology, including responsibility for the annual operating plan and long-term growth strategy for the franchise. Ms Doyle will oversee the alliance management, ENHANZE® business deve

About the Episode: What does the future of eyecare look like? How does a global company stay innovative? Listen to this podcast to hear Dr Xiao-Yu Song, Johnson & Johnson Vision, providing the latest information on J&J Vision's new products, and her approach to innovation.    Key Takeaways:  How to encourage innovation in a large, global company What the current and future eyecare needs are How Johnson & Johnson Vision is expanding and innovating their products, including a first-in-class drug delivery contact lens About the Speaker: Xiao-Yu Song is the Global Head of Research & Development for Johnson & Johnson's eye health business. She has overall R&D responsibility for new product development and life cycle management support as well as portfolio management and innovation governance across all platforms in Johnson & Johnson Vision. Xiao-Yu earned her Ph.D. in Biology from the University of North Carolina at Chapel Hill, her M.S. in Biochemistry and Medical Degree at China

About the Episode: As the COVID-19 pandemic encourages the widespread adoption of decentralized clinical trial models, there are opportunities to optimize existing processes to make clinical research easier for sites and sponsors to conduct, and for patients to participate. Jonathan Andrus, Clinical Ink, discusses his advice as a flexible data collection expert, thoughts on wider adoption of DCTs and where he thinks the future is headed.   Key Takeaways: The role of regulatory guidance, how-to's and industry examplesShifting from a "surviving" to "thriving" mentality in regards to DCTsNext steps for the industry About the Speaker: Jonathan Andrus is Chief Strategy Officer of Clinical Ink. He is responsible for driving the corporate strategic vision, communicating the plan with all those involved, executing the business initiatives, and sustaining implementation efforts. This includes driving important internal initiatives, identifying potential targets for acquisition, and other partnership opportunities

While the idea that trust between sponsors and development partners is integral to success is well known, actually building that relationship requires real effort and empathy from both groups. Today, Dr Skip Sands, Senior Vice President and Senior Medical Officer of Parexel Biotech, discusses practical examples of how to build and maintain that relationship of trust and navigate challenges that arise based on his experience on both sides of the sponsor and CRO partnership.   Key takeaways: How to choose the right development partnerBuilding the relationship infrastructure from the bid process through clinical developmentCommunicating and managing expectations between sponsors and CROs   Guest: Earl “Skip” Sands, MD, MBA, Senior Medical Officer, Parexel Biotech Prior to joining Parexel Biotech as Senior Medical Officer in 2019, Dr Sands served as the Chief Medical Officer for Selecta Biosciences (2015-2019), Targacept (2014-2015) and Plasma Surgical (2013-2014). From 2011 to 2013, he was a consultant to bi

In this podcast, Conference Producer, Andrew Goldstein, reviews what to expect at the 9th annual Chief Medical Officer Summit 360°. The conference will take place October 14-15, 2021 in Boston, MA also with virtual attendance options.  Learn more about the conference taking place October 14-15, 2021 at theconferenceforum.org

In this podcast, first presented at the PODD: Partnership Opportunities in Drug Delivery 2020 conference, you will hear Dr Barbara Lueckel, Roche Pharma Partnering provide her annual review on the drug delivery industry including notable highlights and partnerships that occurred over the past ten years. To learn more about the 2021 PODD: Partnership Opportunities in Drug Delivery conference please visit www.poddconference.com

In this podcast, Conference producer, Mark Scherzer, reviews what to expect at the 8th annual Mobile in Clinical Trials conference. The conference will take place September 27, 2021 in Boston, MA also with virtual attendance options. Learn more here.

In this podcast, Valerie Bowling, Director of the PODD Drug Delivery conference gives a run down summarizing what is being featured at the 11th annual event.  Learn more about the conference taking place October 28-29, 2021 at poddconference.com

Disruptions in the microbiome are increasingly being linked to an associated risk for serious illnesses, opening up vast potential to create a new category of innovative microbiome-based live biotherapeutics to help people live better lives and advance current standards of care.   Today, Dr James Tursi, Chief Scientific Officer of Ferring Pharmaceuticals, discusses study results of Ferring’s Phase III Trial for their microbiome-based live therapeutic (RBX2660), used in the treatment of recurrent C Difficile, and how to harness the potential of the the fast-emerging world of microbiome-based therapeutics.   Key takeaways: Why now is the right time to tackle the microbiomeResults and impact of Ferring's RBX2660 treatmentNext steps for the industry   About the speaker: Dr James Tursi is Chief Scientific Officer, Ferring Pharmaceuticals, responsible for US Clinical Development, Pharmaceutical Development, Medical Affairs, Pharmacovigilance, Project Planning and Regulatory Affairs. Prior to joining Ferring,

DPHARM Executive Director, Valerie Bowling gives a 10 minute run down on what you can expect from DPHARM 2021. Learn more about the conference taking place Septmeber 28-29, 2021 at DPHARMconference.com.

This PharmaTalk Radio episode features Dr Shawn Carbonell, CEO and co-founder of Brazen Bio.  In this conversation, Dr Carbonell describes how the Brazen Incubator, a turn-key biotech startup incubator, hopes to help fledgling entrepreneurs, the common hurdles that prevent startups from getting off the ground, and recruiting underrepresented founders. Dr Carbonell started the incubator, based in Los Angeles, with cofounder Dr Brent Witgen.   About Dr Carbonell and Brazen:  In 2009, Dr Carbonell quit neurosurgery residency to found the clinical stage biotech startup, OncoSynergy, Inc, a UCSF spinout. Brazen Bio, which launched in May 2021, is solving the problem Dr Carbonell had over a decade ago when founding his company. Launching a biotech startup requires laboratory access, specialized equipment and other resources. The Brazen Incubator provides the basic infrastructure to founders, including 24/7 laboratory access, resources and housing.      For more information about our PharmaTalk podcasts, you

In this conversation between two decentralized clinical trial experts, John Reites, CEO of THREAD, and Andy Iverson, Clinical Outcomes Solutions lead at Medtronic, are discussing decentralized clinical trials: where they don’t work yet and how that might change, the considerations for disease indication and trial type, what technology to use, and what an adoption journey could look like.   Key Takeaways: When DCTs don’t work (yet) Technology, operations and knowledge perspectives What a phased approach looks like Identifying the key stakeholders     Speakers:  Andy Iverson is the Clinical Outcomes Solutions lead on the Evidence Optimization Center of Expertise team at Medtronic. In this role he functions as a subject matter expert and project team leader for initiatives related to artificial intelligence, decentralized clinical trials, and interoperability. His career includes 10+ years working with provider and payer systems and data. Andy serves as the Co-Chair of HL7s Biomedical Research and Regu